Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Cash & Current Investments (2023 - 2025)

Immunome's Cash & Current Investments history spans 3 years, with the latest figure at $653.5 million for Q4 2025.

  • For Q4 2025, Cash & Current Investments rose 200.72% year-over-year to $653.5 million; the TTM value through Dec 2025 reached $653.5 million, up 200.72%, while the annual FY2025 figure was $653.5 million, 200.72% up from the prior year.
  • Cash & Current Investments reached $653.5 million in Q4 2025 per IMNM's latest filing, up from $272.6 million in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $653.5 million in Q4 2025 to a low of $38.4 million in Q2 2023.
  • Average Cash & Current Investments over 3 years is $239.0 million, with a median of $254.1 million recorded in 2024.
  • Peak YoY movement for Cash & Current Investments: surged 624.58% in 2024, then dropped 3.7% in 2025.
  • A 3-year view of Cash & Current Investments shows it stood at $138.1 million in 2023, then soared by 57.3% to $217.3 million in 2024, then skyrocketed by 200.72% to $653.5 million in 2025.
  • Per Business Quant, the three most recent readings for IMNM's Cash & Current Investments are $653.5 million (Q4 2025), $272.6 million (Q3 2025), and $268.1 million (Q2 2025).